RES 500-520Alternative Names: RES 500-520
Latest Information Update: 06 Sep 2016
At a glance
- Originator PharmaMax
- Mechanism of Action Oxidoreductase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Respiration disorders
Most Recent Events
- 02 Jan 2013 Launched for Respiration disorders in China (Intranasal)
- 01 Jan 2013 Registered for Respiration disorders in China (Intranasal)